Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Mylan NV (NASDAQ:MYL)

41.71
Delayed Data
As of Mar 27
 +0.75 / +1.83%
Today’s Change
33.60
Today|||52-Week Range
50.40
+9.33%
Year-to-Date
Impax Gains 38% On CEO Appointment, Talk of Sale
Mar 27 / TheStreet.com - Paid Partner Content
Mylan Receives Tentative Approval from FDA for HIV Therapy
Mar 21 / Zacks.com - Paid Partner Content
Can This Pharma Stock Withstand the 'Trump Effect'?
Mar 25 / TheStreet.com - Paid Partner Content
Is Mylan N.V. (MYL) a Great Stock for Value Investors?
Mar 21 / Zacks.com - Paid Partner Content
Largest Insider Trades of the Week
Mar 24 / GuruFocus News - Paid Partner Content
Trumpcare may be healthy for Big Pharma and insurers
Mar 20 / CNNMoney.com
Abbott Sells More Mylan Holdings
Mar 24 / GuruFocus News - Paid Partner Content
Hikma Pharmaceuticals: Amman with a plan
Mar 15 / FT.com - Paid Partner Content
Mylan Hit After Abbott Dumps Shares
Mar 24 / TheStreet.com - Paid Partner Content
Paulson nurses losses as Ackman exits Valeant
Mar 15 / FT.com - Paid Partner Content
Teva Pharma Denies Rumors of Global Workforce Reduction
Mar 24 / Zacks.com - Paid Partner Content
Trump's pledge on drug pricing squeezes pharma stocks
Mar 07 / FT.com - Paid Partner Content
Immunomedics, Mylan Lead Biotech Movers
Mar 24 / TheStreet.com - Paid Partner Content
Trump vows to bring drug prices 'way down'
Mar 07 / CNNMoney.com